Q-omics provides the consensus-scored NADK2 profile across patient tissues and cancer cell-line models. NADK2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, NADK2 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, NADK2 RNA expression shows 20,305 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, THCA, and ACC as cancer lineages where NADK2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NADK2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NADK2 survival associations across molecular data types. NADK2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NADK2 RNA expression–survival associations across cancer types. High NADK2 expression shows unfavorable associations in MESO, KICH, ACC and UCEC, but favorable associations in KIRC and UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for NADK2 RNA expression.
This table summarizes NADK2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for NADK2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NADK2 shows lower tumor expression in THCA, KIRP, CHOL and KICH and higher tumor expression in LUSC and LUAD. The THCA box plot shows higher NADK2 RNA expression in normal versus tumor tissue (log2 FC = −1.000, t-test p < 0.001).
This table shows molecular features associated with NADK2 in patient tissues and cancer cell lines. In patient samples, NADK2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NADK2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
